US FDA clears #Aurangabad unit, classifies as ‘No Action Indicated’

⭕️ US FDA inspection for Aurangabad unit is closed, issues Establishment Inspection Report (#EIR)

US FDA classifies company's #Palghar unit as ‘Voluntary Action Indicated’, issues Establishment Inspection Report (#EIR): Bliss GVS Pharma

US FDA conducted a pre-approval #inspection at Palghar unit from March 13-17, 2023

US FDA issues Establishment Inspection Report (#EIR) for #Atchutapuram, Visakhapatnam unit: Laurus Labs

US FDA issues establishment inspection report (#EIR) for Gagillapur facility in #Hyderabad

Zydus Lifesciences receives #EIR for the injectables manufacturing facility at Zydus Biotech Park, Ahmedabad

#GlandPharma | US FDA issue Establishment Inspection Report (#EIR) for Pashamylaram facility at Hyderabad. EIR from US FDA indicates closure of the #inspection

⭕️ US FDA conducted a #GMP inspection at Pashamylaram unit from August 23-26, 2023

#USFDA issues Establishment Inspection Report (#EIR) for #PiramalPharma’s Riverview manufacturing facility. The Inspection took place on February 7, 2024 & it has been concluded